摘要
目的评价莫西沙星对治疗妇科急性盆腔炎的疗效和安全性。方法将123例带有12种致病菌115菌株的急性盆腔炎患者，随机分为治疗组73例，对照组50例，治疗组口服莫西沙星400mg／d，1次／d，对照组静脉滴注左氧氟沙星注射液500mg／d，1次／d，疗程均为7～14d，进行临床对比研究。结果临床有效率治疗组与对照组分别为95．89％（70／73）和90．00％（45／50）（P〉0．05），致病菌清除率分别为94．20％（65／69）和82．61％（38／46）（P〈0．05），临床未出现严重不良反应。结论莫西沙星左氧氟沙星治疗妇科急性盆腔炎均安全有效。
Objective To evaluate the efficacy and safety of Moxifloxacin in the treatment of women＇ s Acute pelvic inflammatory disease （APID）. Methods All 123 cases of APID With 12 bacterial flora in 115 pathogenes were randomly assigned to treatment group 73 cases and control group 50 cases, with Moxifloxaein, the treatment group, Once-daily Oral 400 mg therapy were done. In the control group with levofloxacin Oncedaily iv treatmented. The treatment courses were all 7 - 14 days. The clinical observation and comparative researth were done. Results The clinical effective rates in the treatment and control groups were 95.89% （70/ 73 ） and 90. 00% （45/50） （ P 〉 005 ） , the bacterial clearance rates were 94.20% （ 65/69 ） and 82. 61% （ 38/ 46 ） （ P 〈 0. 05 ）. No severe adverse reaction in 2 groups. Conclusion Moxifloxacin, levofloxaein is a very effective and safety for APID.
出处
《中国现代药物应用》
2009年第7期14-15,共2页
Chinese Journal of Modern Drug Application
关键词
莫西沙星
左氧氟沙星
急性盆腔炎
Moxifloxacin
Levofloxacin
Once-daily oral
Acute pelvic inflammatory disease
